Eicosapentaenoic and docosahexaenoic acids have different effects on peripheral phospholipase A2 gene expressions in acute depressed patients
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
INTRODUCTION Omega-3 polyunsaturated fatty acids (PUFAs) have been proven critical in the development and management of major depressive disorder (MDD) by a number of epidemiological, clinical and preclinical studies, but the molecular mechanisms underlying this therapeutic action are yet to be understood. Although eicosapentaenoic acid (EPA) seems to be the active component of omega-3 PUFAs' antidepressant effects, the biological research about the difference of specific genetic regulations between EPA and docosahexaenoic acid (DHA), the two main components of omega-3 PUFAs, is still lacking in human subjects. METHODS We conducted a 12-week randomized-controlled trial comparing the effects of EPA and DHA on gene expressions of phospholipase A2 (cPLA2) and cyclooxygenase-2 (COX2), serotonin transporter (5HTT), and Tryptophan hydroxylase 2 (TPH-2) in 27 MDD patients. In addition, the erythrocyte PUFA compositions and the candidate gene expressions were also compared between these 27 MDD patients and 22 healthy controls. RESULTS EPA was associated with a significant decrease in HAM-D scores (CI: -13 to -21, p<0.001) and significant increases in erythrocyte levels of EPA (CI: +1.0% to +2.9%, p=0.001) and DHA (CI: +2.9% to +5.6%, p=0.007). DHA treatment was associated with a significant decrease in HAM-D scores (CI: -6 to -14, p<0.001) and a significant increase in DHA levels (CI: +0.2% to +2.3%, p=0.047), but not of EPA levels. The cPLA2 gene expression levels were significantly increased in patients received EPA (1.9 folds, p=0.038), but not DHA (1.08 folds, p=0.92). There was a tendency for both EPA and DHA groups to decrease COX-2 gene expressions. The gene expressions of COX-2, cPLA2, TPH-2 and 5-HTT did not differ between MDD cases and healthy controls. CONCLUSIONS EPA differentiates from DHA in clinical antidepressant efficacy and in upregulating cPLA2 gene regulations, which supports the clinical observation showing the superiority of EPA's antidepressant effects. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02615405.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nutritional medicine as mainstream in psychiatry
Sarris, J., Logan, A. C., Akbaraly, T. N., Amminger, G. P., Balanzá-Martínez, V., Freeman, M. P., Hibbeln, J., Matsuoka, Y., Mischoulon, D., Mizoue, T., et al. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00051-0 · Cited by 592
Self-citationA meta-analytic review of polyunsaturated fatty acid compositions in patients with depression
Lin, P.-Y., Huang, S.-Y., & Su, K.-P. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.03.018 · Cited by 530
Self-citationLin, P.-Y., & Su, K.-P. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0712 · Cited by 481
Self-citationSu, K.-P., Huang, S.-Y., Chiu, T.-H., Huang, K.-C., Huang, C.-L., Chang, H.-C., & Pariante, C. M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0418 · Cited by 308 · cited 3×
“The detailed step-by-step procedures have been published and described elsewhere (Chang et al., In Press; Chiu et al., 2003; Jadoon et al., 2012; Su et al., 2003; Su et al., 2008; Su et al., 2010; Su et al., 2014).”
MethodInfluentialSelf-citationLin, P.-Y., Mischoulon, D., Freeman, M. P., Matsuoka, Y., Hibbeln, J., Belmaker, R. H., & Su, K.-P. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.111 · Cited by 145 · cited 8×
“More importantly, many clinical trials and meta-analyses (Lin et al., 2012; Lin and Su, 2007; Martins et al., 2012; Sublette et al., 2011), if not all (Bloch and Hannestad, 2012; Marangell et al., 2003; Silvers et al., 2005), have shown that omega-3 PUFAs have antidepressant effects.”
BackgroundInfluentialSelf-citationGałecki, P., Gałecka, E., Maes, M., Chamielec, M., Orzechowska, A., Bobińska, K., Lewiński, A., & Szemraj, J. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.016 · Cited by 141
Self-citationHealy-Stoffel, M., & Levant, B. (2018) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527317666180412153612 · Cited by 133
Chang, J. P.-C., Lai, H.-C., Yang, H.-T., Su, W.-P., Peng, C.-Y., Gałecki, P., Walczewska, A., Pariante, C. M., & Su, K.-P. (2017) · Nutritional Neuroscience · doi:10.1080/1028415x.2015.1123378 · Cited by 19
Self-citation
Cited by
Layé, S., Nadjar, A., Joffre, C., & Bazinet, R. P. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014092 · Cited by 420
“Based on meta-analyses, EPA has been suggested as a predictor of mood disorder treatment efficiency with supplements containing less than 60% of total EPA plus DHA as EPA (between 200 and 2200mg/d) or DHA alone being noneffective (Martins, 2009; Sublette et al., 2011; Mocking et al., 2016).”
BackgroundGiacobbe, J., Benoiton, B., Zunszain, P., Pariante, C. M., & Borsini, A. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00122 · Cited by 159
“been known to reduce depressive symptoms in patients (17, 18) and animal models (19), as well as cognitive symptoms (20).”
BackgroundSelf-citationHealy-Stoffel, M., & Levant, B. (2018) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527317666180412153612 · Cited by 133
Omega-3 fatty acids for depression in adults
Appleton, K. M., Voyias, P. D., Sallis, H. M., Dawson, S., Ness, A. R., Churchill, R., & Perry, R. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004692.pub5 · Cited by 84
Metadata
- Authors
- Su, K.-P., Yang, H.-T., Chang, J. P.-C., Shih, Y.-H., Guu, T.-W., Kumaran, S. S., Gałecki, P., Walczewska, A., & Pariante, C. M.
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 80
- Issue
- Pt C
- Pages
- 227-233
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W2713839620
- Cited by
- 33
- References
- 8
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.